National Vision Surges 129.5% Over the Past Year: What Factors Are Fueling This Uptrend?

National Vision's Remarkable Stock Performance

Over the past year, National Vision (EYE) has delivered impressive returns, with its share price soaring by 129.5%. This surge stands in stark contrast to the medical instruments industry, which experienced a 12% decline, and also outpaces the S&P 500's 23.1% gain during the same period.

Backed by robust fundamentals and promising growth prospects, this Zacks Rank #2 (Buy) stock is currently viewed as a strong option for investors seeking to build wealth.

Company Overview

National Vision is one of the leading optical retailers in the United States. As of June 28, 2025, the company managed a network of 1,240 retail locations under four distinct brands, complemented by related online platforms. National Vision operates primarily through its Owned & Host segment, which includes two proprietary brands: America’s Best Contacts and Eyeglasses and Eyeglass World.

Key Drivers Behind EYE's Growth

The upward momentum in National Vision’s stock is largely attributed to its expanding market share within the Owned & Host segment. This division continues to benefit from increased comparable store sales and the launch of new outlets, with America’s Best serving as the main contributor to revenue.

Efforts to revitalize Eyeglass World are underway, including the appointment of new leadership in early 2025. The company is also enhancing its exam capacity by leveraging remote technology, now available in about two-thirds of its stores. The remote hybrid initiative is progressing, with more in-store doctors trained to conduct remote exams. Additionally, the rollout of electronic health records is expected to boost capacity, streamline operations, and enhance patient satisfaction. A strong performance in the fourth quarter is anticipated to further support these gains.

Image Source: Zacks Investment Research

Investors are closely monitoring National Vision’s ongoing strategic transformation. Management reports that these initiatives are gaining momentum, with a targeted focus on key customer groups leading to improved comparable sales. Newly introduced premium eyewear brands such as Lam, Ted Baker, Jimmy Choo, and HUGO Boss are exceeding sales expectations. The refreshed branding, launched in August 2025, marks a significant step in the company’s transformation.

Looking ahead to 2026, National Vision projects net revenues between $2.033 and $2.091 billion, with adjusted earnings per share expected to range from $0.85 to $1.09.

Operationally, the company achieved a 45 basis point increase in gross margin in the fourth quarter, despite a 13.9% rise in cost of revenues. The operating margin also improved by 186 basis points, contributing to the stock’s positive trajectory.

Potential Challenges Facing EYE

Despite its strengths, National Vision faces several headwinds, including geopolitical uncertainties, supply chain issues, healthcare staffing shortages, and fluctuations in capital markets. Shifts in U.S. trade policy and retaliatory tariffs also pose risks to profitability. In the fourth quarter of 2025, selling, general, and administrative expenses increased by 12.1% year-over-year.

From a financial perspective, the company carries a notable debt load. At the end of the fourth quarter of 2025, National Vision reported $39 million in cash and cash equivalents, $17 million in short-term debt, and $229 million in long-term debt—significantly exceeding its cash reserves. This level of leverage could heighten the company’s vulnerability to adverse economic or industry developments.

Analyst Estimates and Growth Outlook

Over the past month, the Zacks Consensus Estimate for National Vision’s 2026 earnings per share has increased by one cent. The company’s projected long-term EPS growth rate stands at 20.1%, well above the industry average of 12.3%.

Other Promising Medical Stocks

Investors may also want to consider other high-ranking stocks in the medical sector, such as Globus Medical (GMED), Intuitive Surgical (ISRG), and Edwards Lifesciences (EW).

• Globus Medical boasts an earnings yield of 4.9%, outperforming the industry’s negative 0.7%. The company exceeded earnings expectations in three of the last four quarters, with an average surprise of 18.8%. Its shares have climbed 15.5% over the past year, while the industry declined by 4.3%. GMED currently holds a Zacks Rank #1 (Strong Buy).
• Intuitive Surgical, also rated Zacks Rank #1, has an earnings yield of 2.1% compared to the industry’s negative 0.7%. Its shares are up 1.5% year-over-year, and the company has beaten earnings estimates in each of the last four quarters, with an average surprise of 13.2%.
• Edwards Lifesciences carries a Zacks Rank #2 (Buy) and offers an earnings yield of 3.6%. The stock has gained 19.1% over the past year, while the industry fell 4.3%. Edwards beat earnings estimates in three of the last four quarters, with an average surprise of 5.5%.

The Next Wave of AI Investment Opportunities

The artificial intelligence boom has already created significant wealth, but the most well-known companies may not offer the highest returns going forward. Lesser-known AI firms addressing major global challenges could present more lucrative opportunities in the near future.

Get the Latest Stock Recommendations

For the most up-to-date picks from Zacks Investment Research, you can download their report on the 7 Best Stocks for the Next 30 Days.

Free Stock Analysis Reports

• Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
• Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
• Globus Medical, Inc. (GMED): Free Stock Analysis Report
• National Vision Holdings, Inc. (EYE): Free Stock Analysis Report